Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers

Por Liu, Sariah, Nikanjam, Mina, Kurzrock, Razelle
Publicado no Oncotarget (2016)

Dosing targeted and cytotoxic two‐drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013

Por Nikanjam, Mina, Liu, Sariah, Kurzrock, Razelle
Publicado no Int J Cancer (2016)

Dosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patterns

Por Nikanjam, Mina, Patel, Harsh, Kurzrock, Razelle
Publicado no Oncoimmunology (2017)

Population pharmacokinetics of siltuximab: Impact of disease state

Por Nikanjam, Mina, Yang, Jin, Capparelli, Edmund V.
Publicado no Cancer Chemother Pharmacol (2019)

Dosing Three‐Drug Combinations That Include Targeted Anti‐Cancer Agents: Analysis of 37,763 Patients

Por Nikanjam, Mina, Liu, Sariah, Yang, Jincheng, Kurzrock, Razelle
Publicado no Oncologist (2017)

Dosing Oncology Therapeutics in Combination Therapy for Renal Dysfunction: The University of California San Diego Study of Personalized Cancer Therapy to Determine Response and Tox...

Por Nikanjam, Mina, Wing, Jason, Capparelli, Edmund, Kurzrock, Razelle
Publicado no Cureus (2018)

Targeting fusions for improved outcomes in oncology treatment

Por Nikanjam, Mina, Okamura, Ryosuke, Barkauskas, Donald A., Kurzrock, Razelle
Publicado no Cancer (2019)

Review of Precision Cancer Medicine: Evolution of the Treatment Paradigm

Por Tsimberidou, Apostolia M., Fountzilas, Elena, Nikanjam, Mina, Kurzrock, Razelle
Publicado no Cancer Treat Rev (2020)

Persistent Cytarabine and Daunorubicin Exposure after administration of Novel Liposomal Formulation CPX-351: Population Pharmacokinetic Assessment

Por Nikanjam, Mina, Capparelli, Edmund V., Lancet, Jeffrey E., Louie, Arthur, Schiller, Gary
Publicado no Cancer Chemother Pharmacol (2017)

Afebrile Pneumonia in a Patient With Multicentric Castleman Disease on Siltuximab: Infection Without Fever on Anti-Interleukin-6 Therapy

Por Cohen, Philip R, Nikanjam, Mina, Kato, Shumei, Goodman, Aaron M, Kurzrock, Razelle
Publicado no Cureus (2020)

Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD‐L1 expression in cancer patients

Por Nikanjam, Mina, Arguello, David, Gatalica, Zoran, Swensen, Jeff, Barkauskas, Donald A., Kurzrock, Razelle
Publicado no Int J Cancer (2019)

Tumor mutational burden is not predictive of cytotoxic chemotherapy response

Por Nikanjam, Mina, Riviere, Paul, Goodman, Aaron, Barkauskas, Donald A., Frampton, Garrett, Kurzrock, Razelle
Publicado no Oncoimmunology (2020)

Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds

Por Jardim, Denis L., De Melo Gagliato, Débora, Nikanjam, Mina, Barkauskas, Donald A., Kurzrock, Razelle
Publicado no Oncoimmunology (2020)

Vincristine Associated Neuropathy with Antifungal Usage: A Kaiser Northern California Experience

Por Nikanjam, Mina, Sun, Aida, Albers, Mark, Mangalindin, Kristine, Song, Eyun, Vempaty, Hyma, Sam, Danny, Capparelli, Edmund V.
Publicado no J Pediatr Hematol Oncol (2018)

Developmental Pharmacokinetic Changes of Lamivudine in Infants and Children

Por Tremoulet, Adriana H., Nikanjam, Mina, Cressey, Tim R., Chokephaibulkit, Kulkanya, McKinney, Ross, Mirochnick, Mark, Capparelli, Edmund V.
Publicado em 2011

Population pharmacokinetic analysis of oxaliplatin in adults and children identifies important covariates for dosing

Por Nikanjam, Mina, Stewart, Clinton F., Takimoto, Chris H., Synold, Timothy W., Beaty, Orren, Fouladi, Maryam, Capparelli, Edmund V.
Publicado no Cancer Chemother Pharmacol (2015)

Nevirapine Exposure with WHO Pediatric Weight Band Dosing: Enhanced Therapeutic Concentrations Predicted Based on Extensive International Pharmacokinetic Experience

Por Nikanjam, Mina, Kabamba, Desiré, Cressey, Tim R., Burger, David, Aweeka, Francesca T., Acosta, Edward P., Spector, Stephen A., Capparelli, Edmund V.
Publicado em 2012

Relationship between tumor mutational burden and maximum standardized uptake value in 2-[(18)F]FDG PET (positron emission tomography) scan in cancer patients

Por Haghighat Jahromi, Amin, Barkauskas, Donald A., Zabel, Matthew, Goodman, Aaron M., Frampton, Garret, Nikanjam, Mina, Hoh, Carl K., Kurzrock, Razelle
Publicado no EJNMMI Res (2020)

Population Pharmacokinetics of Lopinavir/Ritonavir: Changes Across Formulations and Human Development from Infancy through Adulthood

Por Yang, Jincheng, Nikanjam, Mina, Best, Brookie M., Pinto, Jorge, Chadwick, Ellen G., Daar, Eric S., Havens, Peter L., Rakhmanina, Natella, Capparelli, Edmund V.
Publicado no J Clin Pharmacol (2018)

Development and preclinical pharmacology of a novel dCK inhibitor, DI-87

Por Poddar, Soumya, Capparelli, Edmund V., Rosser, Ethan W., Gipson, Raymond M., Wei, Liu, Le, Thuc, Jung, Michael E., Radu, Caius, Nikanjam, Mina
Publicado no Biochem Pharmacol (2019)